This case report highlights potential inadequacies in standard dalteparin dosing regimens for very obese patients.
Answers are grounded in this paper and cite their sources.
Caution against altering dalteparin dosing from this case alone; leaves open need for prospective pharmacokinetic studies in extreme obesity.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Walden et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: